CClinicalTrials.gg
Not yet recruitingNCT05771337Updated Mar 16, 2023

Circular RNA and Chemerin in Breast Cancer Patient

An observational study in Breast Cancer, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
80
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer.

and To investigate the diagnostic value of hsa_circ_0001785 (Circ-ELP3) and hsa_circ_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3).

andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Read the detailed description

Breast cancer is the most common cancer among women and despite advances in therapy over the past few decades, drug resistance, recurrence, metastasis and the heterogeneity of the cancer continue to be a problem in successful management of the diseases(Hong et al ,2019) .

Circular RNAs (CircRNAs) are single-stranded, covalently closed RNA molecules that are ubiquitous across species ranging from viruses to mammals(Zhou et al 3 .,2020). circRNAs can be divided into two categories including coding and noncoding circRNAs(Li et al., 2019) A new subtype of RNAs is circular RNAs, single-strand RNA molecules with less than 100 to more than 4,000 nucleotides (Lu et al., 2016) and a covalently closedloop structure. These molecules are produced through a backsplicing mechanism, in which the downstream 5'-end of the splice donor joins the upstream 3'-end splice acceptor and forms a product with a circular structure (wang et al., 2017).

Chemerin is a leukocyte chemoattractant widely expressed in many tissues and is known to recruit innate leukocytes.

Recently, more and more studies focus on the relationship between chemerin and cancers and found that chemerin acts an essential role in cancers.(Shin et al,2018) Chemerin expression is different depending on the tumor type (Zhang Y et al, 2013) the clinical significance of chemerin in breast cancer has been only reported by a very limited number of studies (EL Sagheer et al,2018).

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 80 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

female with breast cancer

Inclusion criteria

  • histopathological diagnosis of breast cancer

Exclusion criteria

Exclusion Criteria:

  • history of other types of cancers
  • history of HIV
  • history of any therapeutic interventions in form of chemo or hormonal therapy before specimen collection
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • breast cancer leasion

    Diagnostic Test: blood sample

  • benign breast lesion

    Diagnostic Test: blood sample

Interventions

  • Diagnostic testblood sample

    blood sample

06

What researchers measure

Primary outcomes

  1. measure chemerin and Circular RNA in breast cancer patients

    To elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Song Y, Zhu X, Lin Z, Luo L, Wen D. The potential value of serum chemerin in patients with breast cancer. Sci Rep. 2021 Mar 22;11(1):6564. doi: 10.1038/s41598-021-85986-w. PubMed 33753802 ↗
  • Omid-Shafaat R, Moayeri H, Rahimi K, Menbari MN, Vahabzadeh Z, Hakhamaneshi MS, Nouri B, Ghaderi B, Abdi M. Serum Circ-FAF1/Circ-ELP3: A novel potential biomarker for breast cancer diagnosis. J Clin Lab Anal. 2021 Nov;35(11):e24008. doi: 10.1002/jcla.24008. Epub 2021 Sep 21. PubMed 34545638 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05771337
Lead sponsor
Assiut University
Responsible party
Sandy Nashat Sorial Shokrey (demonstrator in biochemestry departement, Assiut University) — Principal investigator
First posted
Mar 16, 2023
Start date
Oct 2023 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 16, 2023

Study contacts

sandy nashat sorial
Contact
sandybsbsa@yahoo.com
01200693648
abdelhaleem ali abdelhaleem
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion